Skip to main content

AI Does Not Improve Advanced Colorectal Neoplasia Detection Rate

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

TUESDAY, Aug. 29, 2023 -- Computer-aided detection (CADe) during colonoscopy to identify advanced colorectal neoplasias and adenomas and the benefits and harms of CADe were explored in both a randomized trial and systematic review, both published online Aug. 28 in the Annals of Internal Medicine.

Carolina Mangas-Sanjuan, M.D., Ph.D., from the Hospital General Universitario Dr. Balmis in Spain, and colleagues examined the contribution of CADe to colonoscopic detection of advanced colorectal neoplasias as well as other lesions in a randomized controlled trial. A total of 3,213 people with a positive fecal immunochemical test were randomly assigned to colonoscopy with or without computer-aided detection. The researchers found no significant difference in the detection rate of advanced colorectal neoplasia (34.8 versus 34.6 percent for intervention versus controls) or in the mean number of advanced colorectal neoplasias detected per colonoscopy (0.54 versus 0.52, respectively) in the colonoscopy plus CADe versus colonoscopy without CADe groups. There was also no difference in the adenoma detection rate.

Cesare Hassan, M.D., Ph.D., from Humanitas University in Italy, and colleagues quantified the benefits and harms of artificial intelligence CADe across 21 randomized trials in a systematic review and meta-analysis. The analysis included 18,232 patients. The researchers found that the adenoma detection rate was higher in the CADe versus standard colonoscopy group (44.0 versus 35.9 percent; relative risk, 1.24), corresponding to a 55 percent relative reduction in the miss rate. Compared with the standard group, more nonneoplastic polyps were removed in the CADe group (0.52 versus 0.34 per colonoscopy).

"This recent evidence suggests that CADe systems do not meaningfully improve the detection of larger (≥10 mm) clinically significant polyps. This tempers enthusiasm for CADe but does not negate the clear performance benefit for detecting adenomas of all sizes," write the authors of an accompanying editorial.

The study by Mangas-Sanjuan and colleagues was funded by Medtronic.

Abstract/Full Text -- Mangas-Sanjuan (subscription or payment may be required)

Abstract/Full Text -- Hassan (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted August 2023

Read this next

Mortality in Rheumatic Heart Disease Is High

FRIDAY, June 7, 2024 -- Mortality related to rheumatic heart disease (RHD) is high and is correlated with the severity of valve disease, according to a study published online June...

Higher County-Level Prostate Cancer Screening Tied to Better Outcomes

FRIDAY, June 7, 2024 -- Higher county-level prevalence of prostate-specific antigen (PSA) screening is associated with lower odds of advanced disease, all-cause mortality, and...

Metabolic Impact on Offspring Similar for Frozen, Fresh Embryo Transfer

FRIDAY, June 7, 2024 -- For glucose and lipid profiles during early childhood, the impact of frozen embryo transfer (FET) is comparable to that of fresh embryo transfer, according...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.